ROBERTA LA STARZA

A novel KMT2A::AFF1-derived fusion circRNA regulates mitochondrial metabolism in t(4;11) B-cell acute lymphoblastic leukemia

Doron Tolomeo, Michela Bardini, Santina Venuto, Grazia Visci et autres

The t(4;11) translocation, which drives KMT2A::AFF1 fusion gene expression, is associated with poor prognosis in pediatric and adult B-cell Acute Lymphoblastic Leukemia (B-ALL). KMT2A::AFF1 fusion circular RNAs (f-circRNAs) have been identified in B-ALL, though their contribution to leukemia has not yet been …

it (code pays fourni par la source)

Advancing chemogenomic strategies for functional precision medicine in relapsed-refractory T-ALL and ETP-ALL: the GIMEMA ALL2720 trial

Luca Pagliaro, Roberto Rosati, Mariateresa Giaimo, Valentina Bardelli et autres

Despite the vast amount of cancer genomic data, linking mutations to drug efficacy remains challenging. National efforts integrating ex vivo drug response profiling (DRP) with clinical genomics are rare. To address this gap, we designed the GIMEMA ALL2720 trial (NCT04582487), a multicenter …

it, us (code pays fourni par la source)

Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia

Gaetano Cimino, Rebecca Sembenico, Francesco Zorutti, Simonetta Saldi et autres

Nucleoporin 98 (NUP98) rearrangements occur in approximately 2-3% of myeloid neoplasms and involve more than 40 partner genes. In acute myeloid leukemia (AML), they define distinct entities associated with adverse prognosis, high rates of chemoresistance, and frequent relapse even after allogeneic hematopoietic …

it (code pays fourni par la source)

Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia

Anna Montanaro, Gregorio Monica, Raffaella Zamponi, Anna D’Antuono et autres

ABSTRACT: Driver mutations in T-cell acute lymphoblastic leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for target discovery and therapeutic …

it, us, nl (code pays fourni par la source)

Advancing Chemogenomic Strategies for Functional Precision Medicine in Relapsed/Refractory T-ALL and ETP-ALL: TheGimema ALL2720 Trial

Luca Pagliaro, Roberto Rosati, Mariateresa Giaimo, Valentina Bardelli et autres

it (code pays fourni par la source)

Deregulation of FOXF1 / FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia

Danika Di Giacomo, Petri Pölönen, Valentina Bardelli, Shunsuke Kimura et autres

ABSTRACT: Despite great progress in understanding the genomic basis of immature T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL) and acute leukemias of ambiguous lineage, there are still cases that lack defining genetic markers, complicating risk stratification, and limiting targeted therapeutic options. Recent studies …

us, it, jp (code pays fourni par la source)

DDX10 RNA Helicase: Structure, Function, and Oncogenic Roles Across Solid and Hematologic Tumors

Giorgia Isinelli, Genny Scacci, Arianna Capocchia, Carla Emiliani et autres

DEAD-box (DDX) RNA helicases are essential regulators of RNA metabolism and gene expression. Among them, DDX10 remains poorly characterized despite growing evidence supporting its involvement in human diseases. This review provides a comprehensive analysis of DDX10, from its structural and functional features …

it (code pays fourni par la source)

Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study

Marco Cerrano, Davide Lazzarotto, Eleonora Boscaro, Erika Borlenghi et autres

Not available.

it, us (code pays fourni par la source)

14Q+ CHROMOSOME MARKER IN A T‐CELL‐RICH B‐CELL LYMPHOMA

ROBERTA LA STARZA, ANA AVENTIN, D Falzetti, Michel S. Stul et autres